Merck & Co. Inc.

03/06/2021 | Press release | Distributed by Public on 03/05/2021 23:26

Ridgeback Biotherapeutics and Merck Announce Preliminary Findings from a Phase 2a Trial of Investigational COVID-19 Therapeutic Molnupiravir